News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
101 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53928)
2023 (42564)
2024 (37441)
2025 (33091)
2026 (18664)
Month
January (2433)
February (2866)
March (3029)
April (3115)
May (3356)
June (2725)
July (1140)
Day
1 (121)
2 (97)
3 (8)
5 (6)
6 (80)
7 (151)
8 (89)
9 (81)
10 (30)
13 (140)
14 (106)
15 (102)
16 (129)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
Day
1
2
3
5
6
7
8
9
10
13
14
15
16
Podcast
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Biogen’s new data, presented at the Alzheimer’s Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.
July 15, 2026
·
1 min read
·
Jef Akst
Press Releases
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
July 15, 2026
·
9 min read
Press Releases
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
July 15, 2026
·
3 min read
Press Releases
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
July 15, 2026
·
4 min read
Press Releases
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma
July 15, 2026
·
4 min read
Press Releases
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
July 15, 2026
·
4 min read
Press Releases
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
July 15, 2026
·
20 min read
Press Releases
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
July 15, 2026
·
1 min read
Approvals
Celcuity wins breast cancer nod, securing ‘differentiated foothold’ in market
Celcuity’s first approved drug, Revtorpyk, is indicated for the second-line treatment of advanced HER2- breast cancer patients without
PIK3CA
mutations—a key use distinction that sets it apart from other PIK3/AKT blockers in the space, according to Jefferies.
July 15, 2026
·
2 min read
·
Tristan Manalac
Press Releases
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
July 15, 2026
·
19 min read
Previous
4 of 11
Next
